TMO|Analyst Targets
TMO|Company Info
TMO|Insider Trading
TMO|Fundamentals
TMO|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $6.40 | - | - |
| Q2'26 | $6.37 | $6.03 | -5.3% |
| Q1'26 | $5.74 | $5.44 | -5.2% |
| Q4'25 | $6.51 | $6.57 | +0.9% |
| Q3'25 | $5.50 | $5.79 | +5.3% |
| Q2'25 | $5.23 | $5.36 | +2.5% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $12.1B | - | - |
| Q2'26 | $11.8B | $12.0B | +1.5% |
| Q1'26 | $11.8B | $11.0B | -6.7% |
| Q4'25 | $12.1B | $12.2B | +1.2% |
| Q3'25 | - | $11.1B | - |
| Q2'25 | - | $10.9B | - |
TMO|Monthly Returns
Market Data
TMO Stock Snapshot
- Market cap
- 244.85B
- P/E ratio
- 35.1
- Day range
- $659.00 – $681.50
- News sentiment
- 69/100 · Bullish
- Analyst target
- $683.84 (+1.6%)
- Consensus
- Buy · 38 analysts
TMO sits near its 52-week high with the technical picture unresolved. Positioning shifts among large allocators, not retail flow, set the tone for a name this size.
Reverse DCF
What growth is priced into TMO?
At today's price, Thermo Fisher Scientific Inc. needs to grow free cash flow about 26.1% a year for the next 10 years to justify its valuation at a 8.45% cost of capital. Over its actual history it has compounded free cash flow at 12.6% a year, so the market is asking for 13.5 percentage points above its own delivered rate. On that basis TMO looks priced above what its own growth record supports.
- Implied FCF growth
- 26.1%
- Historical FCF CAGR
- 12.6%
- Growth gap
- +13.5 pts
- Verdict
- RICH
- Discount rate (WACC)
- 8.45%
- Beta
- 0.83
Behaviour On Record
What TMO's own history says about today's numbers
- Realized volatility (21d)
- 24.9% 66th pct
- Below its peak
- -1.8%
- vs 200-day average
- +22.2%
- Up days (1y)
- 50%
Thermo Fisher Scientific Inc. is currently running 24.9% annualised volatility over the last 21 sessions. Measured against TMO's own 13 years of daily returns rather than a market-wide average, that is the 66th percentile — a little above its own norm, against a typical reading of 22.2%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.
TMO is trading -1.8% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -16.6%, and the deepest was -35.6% in 2025. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.
Price sits +22.2% from its 200-day moving average. Against every other day in its history, that gap ranks at the 95th percentile — a wider gap than this stock usually carries. Over the past year TMO closed higher on 50% of sessions, and it is currently 4 sessions into a rising streak.
On October specifically: over 14 years of records, TMO finished the month higher 8 of 14 times, with a median return of +1.6% and an average of +0.7%. Its strongest month historically has been July at +7.4% on average, its weakest February at -2.9%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.
Overnight risk is measurable too: TMO has opened more than 2% away from the prior close in 93 of 3,268 sessions (2.8% of the time), with the largest gaps running +6.1% and -9.0%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.
Across the last 3 dated reports on file, TMO moved an average of 0.7% in the session after earnings, closing higher 1 of those 3 times, with a median move of -0.5% and a largest of -1.6%.
All figures computed from 3,269 daily closes between 2013-10-15 and 2026-10-14, split-adjusted, recomputed daily. Percentiles are against TMO's own 13-year history, not a peer group or index.
Sector Rotation
Is money rotating into or out of TMO's sector?
Thermo Fisher Scientific Inc. sits in the Health Care sector, currently ranked 2nd of 12 GICS sectors by relative-strength rotation score (leading).
- Sector rank
- #2 of 12
- Sector state
- Leading
- Sector rotation score
- 82
Analyst Rating Changes
Are analysts turning bullish or bearish on TMO?
Morgan Stanley most recently reiterated its rating on Thermo Fisher Scientific Inc. to Overweight on Oct 13, 2026 with a price target of $730 (from $650). Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.
- Latest action
- Morgan Stanley — Overweight
- 90-day upgrades
- 0
- 90-day downgrades
- 0
- Net rating momentum
- 0
Peers & ETF holders
TMO peers & ETF holders
Diagnostics & ResearchMarket cap · today
News Sentiment Analysis
Sentiment gathered from recent headlines
Recent News Coverage
Most recent articles, ranked by recency (click to expand).
Technical Analysis
Real-time indicators across multiple timeframes
| Manager | Trend | Shares Held | % of Co. | Position Value | Filed |
|---|---|---|---|---|---|
| Vanguard Group Inc | ▲ Buy | 34,133,702 | 9.29% | $19.78B | 2026-01-29 |
| BlackRock, Inc. | ▲ Buy | 30,919,632 | 8.42% | $15.50B | 2026-08-07 |
| FMR LLC (Fidelity) | ▲ Buy | 14,084,488 | 3.84% | $7.06B | 2026-08-13 |
| Morgan Stanley | ▼ Sell | 10,763,066 | 2.93% | $5.40B | 2026-08-13 |
| JPMorgan Chase & Co | ▲ Buy | 8,503,527 | 2.32% | $4.31B | 2026-08-12 |
| Geode Capital Management, LLC | ▼ Sell | 8,382,401 | 2.28% | $4.18B | 2026-08-12 |
| Capital World Investors | ▼ Sell | 6,195,370 | 1.69% | $3.11B | 2026-08-12 |
| Norges Bank | ▼ Sell | 5,087,903 | 1.39% | $2.55B | 2026-08-12 |
| Capital Research Global Investors | ▼ Sell | 4,147,545 | 1.13% | $2.08B | 2026-08-12 |
| Bank of America Corp | ▼ Sell | 3,895,265 | 1.06% | $1.95B | 2026-08-14 |
| Northern Trust Corp | ▼ Sell | 3,328,836 | 0.91% | $1.67B | 2026-08-13 |
| Goldman Sachs Group Inc | ▼ Sell | 2,957,066 | 0.81% | $1.48B | 2026-08-14 |
| Fisher Asset Management, LLC | ▲ Buy | 2,915,715 | 0.79% | $1.46B | 2026-08-04 |
| Invesco Ltd. | ▼ Sell | 2,179,010 | 0.59% | $1.09B | 2026-08-14 |
| Viking Global Investors LP | ▲ Buy | 1,937,415 | 0.53% | $971.34M | 2026-08-14 |
| AllianceBernstein L.P. | ▼ Sell | 1,849,037 | 0.50% | $908.86M | 2026-08-14 |
| Wells Fargo & Company | ▲ Buy | 1,458,431 | 0.40% | $731.20M | 2026-08-14 |
| Loomis Sayles & Co L P | ▼ Sell | 1,315,185 | 0.36% | $659.38M | 2026-08-14 |
| Temasek Holdings (Private) Ltd | ▼ Sell | 1,163,729 | 0.32% | $583.45M | 2026-08-07 |
| Farallon Capital Management LLC | ▲ Buy | 1,049,185 | 0.29% | $526.02M | 2026-08-14 |
| Wellington Management Group LLP | ▼ Sell | 979,181 | 0.27% | $490.92M | 2026-08-14 |
| D1 Capital Partners L.P. | ▲ Buy | 817,123 | 0.22% | $409.67M | 2026-08-14 |
| Neuberger Berman Group LLC | ▼ Sell | 667,506 | 0.18% | $334.66M | 2026-08-13 |
| Citigroup Inc | ▲ Buy | 650,976 | 0.18% | $326.37M | 2026-08-03 |
| Janus Henderson Group plc | ▼ Sell | 660,258 | 0.18% | $324.56M | 2026-05-18 |
| Member | Chamber | State | Type | Amount | Traded | Filed |
|---|---|---|---|---|---|---|
| Dan Newhouse | House | WA04 | ▼ Sell | $1K - $15K | 2026-07-10 | 2026-07-17 |
| Dwight Evans | House | PA03 | ▼ Sell | $1K - $15K | 2026-05-07 | 2026-05-15 |
| Alan Armstrong | Senate | OK | ▲ Buy | $1K - $15K | 2026-03-27 | 2026-07-21 |
| Lisa McClain | House | MI09 | ▼ Sell | $1K - $15K | 2025-10-31 | 2025-11-21 |
| Lisa McClain | House | MI09 | ▼ Sell | $1K - $15K | 2025-10-30 | 2025-11-21 |
| Lisa McClain | House | MI09 | ▲ Buy | $1K - $15K | 2025-10-30 | 2025-11-21 |
| Valerie Hoyle | House | OR04 | ▼ Sell | $1K - $15K | 2025-09-23 | 2025-10-10 |
| Kelly Louise Morrison | House | MN03 | ▼ Sell | $15K - $50K | 2025-08-19 | 2025-09-11 |
| Julia Letlow | House | LA05 | ▲ Buy | $1K - $15K | 2025-07-25 | 2026-01-13 |
| Lisa McClain | House | MI09 | ▲ Buy | $1K - $15K | 2025-07-22 | 2025-08-13 |
| Angus King | Senate | - | ▼ Sell | $1K - $15K | 2025-07-21 | 2025-08-18 |
| Lisa McClain | House | MI09 | ▼ Sell | $1K - $15K | 2025-06-10 | 2025-08-13 |
| Valerie Hoyle | House | OR04 | ▲ Buy | $1K - $15K | 2025-06-06 | 2025-09-12 |
| Richard W. Allen | House | GA12 | ▼ Sell | $15K - $50K | 2025-05-16 | 2025-06-18 |
| Rob Bresnahan | House | PA08 | ▲ Buy | $15K - $50K | 2025-05-15 | 2025-05-31 |
| Thomas H. Kean | House | NJ07 | ▲ Buy | $1K - $15K | 2025-05-05 | 2025-06-17 |
| Julia Letlow | House | LA05 | ▼ Sell | $1K - $15K | 2025-04-28 | 2026-01-13 |
| Bruce Westerman | House | AR04 | ▼ Sell | $1K - $15K | 2025-04-21 | 2025-05-12 |
| Richard W. Allen | House | GA12 | ▼ Sell | $15K - $50K | 2025-04-11 | 2025-05-15 |
| Dan Newhouse | House | WA04 | ▼ Sell | $1K - $15K | 2025-04-11 | 2025-05-16 |
| Rob Bresnahan | House | PA08 | ▼ Sell | $15K - $50K | 2025-04-08 | 2025-04-28 |
| Julie Johnson | House | TX32 | ▼ Sell | $1K - $15K | 2025-04-07 | 2025-05-14 |
| Jefferson Shreve | House | IN06 | ▼ Sell | $15K - $50K | 2025-04-07 | 2025-05-08 |
| Greg Landsman | House | OH01 | ▼ Sell | $1K - $15K | 2025-03-27 | 2025-04-08 |
| Valerie Hoyle | House | OR04 | ▼ Sell | $1K - $15K | 2025-03-03 | 2025-09-12 |